Armistice Capital LLC Buys New Stake in Kazia Therapeutics Limited (NASDAQ:KZIA)

Armistice Capital LLC bought a new stake in Kazia Therapeutics Limited (NASDAQ:KZIAFree Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 2,475,555 shares of the company’s stock, valued at approximately $1,088,000. Armistice Capital LLC owned about 15.15% of Kazia Therapeutics at the end of the most recent reporting period.

Kazia Therapeutics Trading Up 4.1 %

Kazia Therapeutics stock traded up $0.01 during midday trading on Wednesday, hitting $0.26. 27,572 shares of the company’s stock were exchanged, compared to its average volume of 584,367. Kazia Therapeutics Limited has a 12-month low of $0.19 and a 12-month high of $1.34. The firm’s 50 day simple moving average is $0.32 and its 200 day simple moving average is $0.35.

Kazia Therapeutics Profile

(Free Report)

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.

Featured Stories

Want to see what other hedge funds are holding KZIA? Visit to get the latest 13F filings and insider trades for Kazia Therapeutics Limited (NASDAQ:KZIAFree Report).

Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with's FREE daily email newsletter.